This session will focus on the latest developments in the Korean biopharmaceutical market and look in-depth at R&D trends.
Korea has emerged as a leading biopharmaceutical market, valued at around $18.6 billion with a annual growth rate of 7% from 2012 to 2018. Furthermore, the domestic biopharmaceutical industry is expanding internationally with the advancement of innovative technologies and has become a key growth engine for the Pharma industry in Korea.
hear from global consultants on the strengths of Korea's Biopharma industry, who will share practical information and data on R&D, RA, Business Development and Marketing strategies.
This is a great opportunity to gain cutting-edge insight from businesses who are scaling up for the future and building partnerships with domestic pharmaceutical companies.
- Peptron : Smart Depot Platform and its applications
- Olix Pharmaceuticals : OliX Pharmaceuticals: RNAi Therapeutics Company
- HK inno.N : World P-CAB Leader, HK inno.N
- Daewoong Pharmaceutical : Research & Development innovation with Daewoong's Platform Technology
- Huons : Huons Corporate Presentation: Hu007 and Hutox
- Ceres F&D : Introduction of Hyaluronidase and Tacrolimus
Aired as part of the CPHI Festival of pharma
KR